Laura Hunt, MD
Pulmonary Disease · Franklin, TNNPI 1114019528
Payments from drug & device makers
Across 195 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$637
- AstraZeneca$382
- Boehringer Ingelheim$348
- Insmed, Inc.$259
- Actelion Pharmaceuticals US, Inc.$214
- Philips North America LLC$126
- plus $2K from 37 others
What the payments were for
- Food & beverage$3,45795%
- Education$2005%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 45 | $637 |
| AstraZeneca | 18 | $382 |
| Boehringer Ingelheim | 17 | $348 |
| Insmed, Inc. | 12 | $259 |
| Actelion Pharmaceuticals US, Inc. | 12 | $214 |
| Philips North America LLC | 6 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $100 |
| Sunovion Pharmaceuticals Inc. | 8 | $92 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Novartis | 6 | $89 |
| Grifols USA, LLC | 4 | $88 |
| Mallinckrodt Enterprises LLC | 3 | $82 |
| Regeneron Healthcare Solutions, Inc. | 4 | $79 |
| Portola Pharmaceuticals, LLC | 3 | $79 |
| Johnson & Johnson | 3 | $78 |
| Mylan Specialty L.p. | 4 | $77 |
| Merck | 4 | $66 |
| Genentech USA, Inc. | 4 | $65 |
| Sanofi | 3 | $58 |
| Circassia Inc. | 3 | $55 |
| CSL Behring | 2 | $54 |
| Teva Pharmaceuticals USA, Inc. | 3 | $44 |
| Electromed, Inc. | 3 | $38 |
| Pfizer | 2 | $38 |
| Amgen | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 1 | $35 |
| Paratek Pharmaceuticals, Inc. | 2 | $34 |
| Verona Pharma, Inc. | 1 | $31 |
| 3b Medical, Inc. | 1 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Covidien LP | 1 | $24 |
| Alkermes, Inc. | 1 | $23 |
| Harmony Biosciences LLC | 1 | $22 |
| Baxter Healthcare | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Gilead | 1 | $17 |
| Bayer | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Pulmonx Corporation | 1 | $14 |
| Medtronic | 1 | $13 |
| AbbVie | 1 | $12 |
| Eisai Inc. | 1 | $12 |
How this compares
$3,657 in reported general payments places this provider in the 45th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 650 | $503,713 |
| Dupixent PenDupilumab | 80 | $295,786 |
| OfevNintedanib Esylate | 27 | $245,086 |
| Breo ElliptaFluticasone/Vilanterol | 393 | $195,600 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 188 | $155,417 |
| Dupixent SyringeDupilumab | 24 | $87,195 |
| Arnuity ElliptaFluticasone Furoate | 247 | $75,807 |
| Advair HfaFluticasone Propion/Salmeterol | 93 | $47,983 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 74 | $33,858 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 133 | $31,612 |
| Qvar RedihalerBeclomethasone Dipropionate | 92 | $31,127 |
| SymbicortBudesonide/Formoterol Fumarate | 79 | $23,875 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 75 | $21,556 |
| DuleraMometasone/Formoterol | 47 | $21,353 |
| Spiriva RespimatTiotropium Bromide | 28 | $20,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta | $637 | $808,9771,364 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $348 | $265,10655 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $382 | $188,541303 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $44 | $31,12792 claims |
| MerckDulera | $66 | $21,35347 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Franklin
- Aaron MilstoneFranklin$2.4M
- Fabien MaldonadoNashville$2.5M
- John SwisherKnoxville$2.3M
- James TolleNashville$2.3M
- Lisa LancasterNashville$1.6M
- Ivan RobbinsNashville$1.3M
- Clyde SouthwellHendersonville$801K
- Krishnendu BhadraChattanooga$631K
- Eric WeaverKnoxville$492K
- Rajiv DhandKnoxville$426K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.